Registration Dossier
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 214-946-9 | CAS number: 1222-05-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Skin sensitisation
Administrative data
- Endpoint:
- skin sensitisation: in vivo (non-LLNA)
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1996
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Selection criteria for dose selection were not clear. reliability was assessed in the Risk Assessment Report under the Existing substances Regulation.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 996
Materials and methods
Test guideline
- Qualifier:
- no guideline available
- Principles of method if other than guideline:
- see: any other information on materials and methods
- GLP compliance:
- no
- Type of study:
- guinea pig maximisation test
Test material
- Reference substance name:
- 1,3,4,6,7,8-hexahydro-4,6,6,7,8,8-hexamethylindeno[5,6-c]pyran
- EC Number:
- 214-946-9
- EC Name:
- 1,3,4,6,7,8-hexahydro-4,6,6,7,8,8-hexamethylindeno[5,6-c]pyran
- Cas Number:
- 1222-05-5
- Molecular formula:
- C18H26O
- IUPAC Name:
- 4,6,6,7,8,8-hexamethyl-1H,3H,4H,6H,7H,8H-indeno[5,6-c]pyran
- Details on test material:
- The test substance was the commercially available grade of HHCB, which is ca. 65% HHCB in DEP
Constituent 1
In vivo test system
Test animals
- Species:
- guinea pig
- Strain:
- Dunkin-Hartley
- Sex:
- male/female
- Details on test animals and environmental conditions:
- Six male and four female Albino Dunkin/Hartley guinea pigs (weight 316-350 g)
Study design: in vivo (non-LLNA)
Inductionopen allclose all
- Route:
- intradermal
- Vehicle:
- other: 0.01% dodecylbenzene sulphonate in 0.9% saline (DOBS/saline) for the intradermal induction injection, 70% acetone / 30% polyethylene glycol 400 (aceton/PEG400) for the challenge patch.
- Concentration / amount:
- Intradermal injection: 0.5% Galaxolide 50 (equivalent to 0.325% HHCB) in vehicle (0.01% dodecylbenzene sulphonate in 0.9% saline (DOBS/saline))
Induction patch: 100% Galaxolide 50 (equivalent to 65% HHCB)
Challenge patch: 25% Galaxolide 50 (equivalent to 16.25% HHCB) in vehicle (70% acetone / 30% polyethylene glycol 400 (aceton/PEG400))
Challengeopen allclose all
- Route:
- epicutaneous, occlusive
- Vehicle:
- other: 0.01% dodecylbenzene sulphonate in 0.9% saline (DOBS/saline) for the intradermal induction injection, 70% acetone / 30% polyethylene glycol 400 (aceton/PEG400) for the challenge patch.
- Concentration / amount:
- Intradermal injection: 0.5% Galaxolide 50 (equivalent to 0.325% HHCB) in vehicle (0.01% dodecylbenzene sulphonate in 0.9% saline (DOBS/saline))
Induction patch: 100% Galaxolide 50 (equivalent to 65% HHCB)
Challenge patch: 25% Galaxolide 50 (equivalent to 16.25% HHCB) in vehicle (70% acetone / 30% polyethylene glycol 400 (aceton/PEG400))
- No. of animals per dose:
- 10
- Details on study design:
- 1st application: Induction 0.5 % intracutaneous
2nd application: Induction 100 % occlusive epicutaneous
3rd application: Challenge 25 % occlusive epicutaneous - Challenge controls:
- Eight animals were treated as controls and received induction and challenge treatments similar to the test pigs minus the test material.
Results and discussion
In vivo (non-LLNA)
Resultsopen allclose all
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- test chemical
- Dose level:
- 25% Galaxolide
- No. with + reactions:
- 2
- Total no. in group:
- 10
- Clinical observations:
- very faint erythema (score 0.5)
- Remarks on result:
- other: Reading: 1st reading. . Hours after challenge: 24.0. Group: test group. Dose level: 25% Galaxolide. No with. + reactions: 2.0. Total no. in groups: 10.0. Clinical observations: very faint erythema (score 0.5).
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- test chemical
- Dose level:
- 25% Galaxolide
- No. with + reactions:
- 3
- Total no. in group:
- 10
- Clinical observations:
- very faint erythema (score 0.5)
- Remarks on result:
- other: Reading: 2nd reading. . Hours after challenge: 48.0. Group: test group. Dose level: 25% Galaxolide. No with. + reactions: 3.0. Total no. in groups: 10.0. Clinical observations: very faint erythema (score 0.5).
- Reading:
- rechallenge
- Group:
- test chemical
- Dose level:
- 25% Galaxolide
- Total no. in group:
- 10
- Remarks on result:
- other: Reading: rechallenge. Group: test group. Dose level: 25% Galaxolide. Total no. in groups: 10.0.
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- test chemical
- Dose level:
- 25% Galaxolide
- No. with + reactions:
- 3
- Total no. in group:
- 10
- Clinical observations:
- very faint erythema (Score 0,5)
- Remarks on result:
- other: Reading: 1st reading. . Hours after challenge: 24.0. Group: test group. Dose level: 25% Galaxolide. No with. + reactions: 3.0. Total no. in groups: 10.0. Clinical observations: very faint erythema (Score 0,5).
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- test chemical
- Dose level:
- 25% Galaxolide
- No. with + reactions:
- 1
- Total no. in group:
- 10
- Clinical observations:
- very faint erythema (score 0,5)
- Remarks on result:
- other: Reading: 2nd reading. . Hours after challenge: 48.0. Group: test group. Dose level: 25% Galaxolide. No with. + reactions: 1.0. Total no. in groups: 10.0. Clinical observations: very faint erythema (score 0,5).
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- test chemical
- Dose level:
- 25% Galaxolide
- No. with + reactions:
- 1
- Total no. in group:
- 10
- Clinical observations:
- very faint erythma (score 0,5)
- Remarks on result:
- other: Reading: 1st reading. . Hours after challenge: 24.0. Group: test group. Dose level: 25% Galaxolide. No with. + reactions: 1.0. Total no. in groups: 10.0. Clinical observations: very faint erythma (score 0,5).
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- test chemical
- Dose level:
- 25% Galaxolide
- No. with + reactions:
- 0
- Total no. in group:
- 10
- Remarks on result:
- other: Reading: 2nd reading. . Hours after challenge: 48.0. Group: test group. Dose level: 25% Galaxolide. No with. + reactions: 0.0. Total no. in groups: 10.0.
Any other information on results incl. tables
At 24 hours, very faint erythema (score 0.5) was found in 2/10 animals at challenge 1, 3/10 animals at challenge 2, and 1/10 at challenge 3. At 48 hours, 3/10, 1/10 and 0/10 had very faint erythema. At challenge at 24 hours, only one animal showed very faint erythema to faint erythema.
Applicant's summary and conclusion
- Interpretation of results:
- not sensitising
- Remarks:
- Migrated information
- Conclusions:
- Except for one equivocal response in one animal, no evidence that the material was a sensitiser was seen. Classification: not sensitizing
- Executive summary:
Galaxolide (65% HHCB in DEP) has been subjected to a non-GLP guinea pig maximization test. The used doses of Galaxolide were 0.5% in 0.01% dodecylbenzene sulphonate in 0.9% saline (DOBS/saline) for the intradermal injection, 100% for the induction patch, and 25% in 70% acetone/30% polyethylene glycol 400 (acetone/PEG400) for the challenge patch. These doses were selected based on preliminary irritation tests using 0.1, 0.25, 0.5, 1.0 and 2.0% Galaxolide concentrations for intradermal injections, however the selection criteria were not clear. The actual concentrations of HHCB are 0.325%, 65%, and 16.25%, respectively. Ten (six male, four female) Albino Dunkin/Hartley guinea pigs (weight 316-350g) were tested on a 2cm x 4cm area of skin in the dorsal shoulder area, clipped free of fur. Induction consisted of a 0.1 ml intradermal injection of 0.325% HHCB in DOBS/saline and 0.1 ml 50% Freund’s Complete Adjuvant in 0.9% saline. This was followed one week later by a 48 hr occluded patch (filter paper attached by adhesive tape to polythene backing) saturated with 65% HHCB). The patch was applied at the same 2 cm by 4cm area after freshly shaving the skin. Challenge applications were made 14 days later at a freshly shaved naïve site by saturation of an 8mm diameter filter paper patch with 16.25% HHCB in 70% acetone/30% PEG 400. Eight animals were treated as controls and received induction and challenge treatments similar to the test pigs minus the test material. Two repeat challenges at weekly intervals were conducted. At 24 hours, very faint erythema (score 0.5) was found in 2/10 animals at challenge 1, 3/10 animals at challenge 2, and 1/10 at challenge 3. At 48 hours, 3/10, 1/10 and 0/10 had very faint erythema. At challenge at 24 hours, only one animal showed very faint erythema to faint erythema. Except for one equivocal response in one animal, no evidence that the material was a sensitiser was seen (Basketter, 1996).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

Route: .live1